DNA Damage-Mediated Induction of a Chemoresistant Niche
While numerous cell-intrinsic processes are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the tumor microenvironment on therapeutic outcome. Here, we use a well-established mouse model of Burkitt's lymphoma to show that paracrine facto...
| Main Authors: | , |
|---|---|
| Other Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier B.V.,
2015-03-19T14:57:12Z.
|
| Subjects: | |
| Online Access: | Get fulltext |
| Summary: | While numerous cell-intrinsic processes are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the tumor microenvironment on therapeutic outcome. Here, we use a well-established mouse model of Burkitt's lymphoma to show that paracrine factors in the tumor microenvironment modulate lymphoma cell survival following the administration of genotoxic chemotherapy. Specifically, IL-6 and Timp-1 are released in the thymus in response to DNA damage, creating a "chemo-resistant niche" that promotes the survival of a minimal residual tumor burden and serves as a reservoir for eventual tumor relapse. Notably, IL-6 is released acutely from thymic endothelial cells in a p38-dependent manner following genotoxic stress, and this acute secretory response precedes the gradual induction of senescence in tumor-associated stromal cells. Thus, conventional chemotherapies can induce tumor regression while simultaneously eliciting stress responses that protect subsets of tumor cells in select anatomical locations from drug action. National Institutes of Health (U.S.) (NIH RO1 CA128803) David H. Koch Institute for Integrative Cancer Research at MIT (Ludwig Center for Molecular Oncology)) Massachusetts Institute of Technology. Department of Biology (Rita Allen Fellow) |
|---|